Bibliography
- CHUANG Y, SWANSON R, RAJA S et al.: Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J. Biol. Chem. (2001) Feb 7: epub ahead of print [wwwjbc.org/cgi/reprint/M011550200v1.pdf] .
- BLANK M, CINES D, AREPALLY G et al., Pathogenicity of human anti-platelet Factor 4 (Pf4)/heparin in viva generation of mouse anti-Pf4/heparin and induction of thrombocytopenia by heparin. Clin. Exp. Immunol (1997) 108(2):333–339.
- FAREED J, HOPPENSTEADT D, BICK R: An update on heparins at the beginning of the new millennium. Semin. Thromb. Hemostas. (2000) 26 (Suppl. 1):5–21.
- •A review of heparin, LMWH and small molecule inhibitors.
- CAIOLA E: Heparin-induced thrombocytopenia: how to manage it, how to avoid it. Cleve. an. J. Med. (2000) 67 (9) :621–624.
- SOLUM N, Procoag-ulant expression in platelets and defects leading to clinical disorders. Arterioscler. Thromb. Vasc. Biol. (1999) 19 (12) :2841–2846.
- ANDERSON J, FREDENBURGH J, STAFFORD A et al. Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagu-lant by inhibiting intrinsic tenase and prothrombi-nase. J. Biol. Chem. (2001) 276(13):9755–9761.
- WALLENTIN L, Low molecular weight heparin in unstable coronary artery. Exp. Opin. Invest. Drugs (2000) 9(3):581–592.
- AL-OBEIDI F, OSTREM J: Factor Xa inhibitors. Exp. Opin. Ther. Patents, (1999) 9(7):931–953.
- •A good review covering the different patents on FXa inhibitors.
- HARA T, YOKOHAMA Y, ISHIHARA H eta].: Dx-9065a, a new synthetic, potent anticoagulant and selective inhibitor for Factor Xa. Thromb. Haemostas. (1994) 71:314–319.
- •The original drug which started the search for small molecule FXa inhibitors.
- KAMATA K, KAWAMOTO H, HONMA T et al., Structuralbasis for chemical inhibition of human blood coagula-tion Factor Xa. Proc. Nati Acad. Sci. USA. (1998) 95(12): 6630–6635.
- PINTO D, ORWAT M, WANG S et al: Discovery of1 43 -(amin om ethyl)ph enyli-N-3 -fluor o-2'-(m ethylsul-fony1)41, 1 t-biphenyl]-4 -Y1]-3 -(tr ifluo r om e thyl)-1 h - pyrazole-5-carbox amide (Dpc423), a highly potent, selective and orally bioavailable inhibitor of blood coagulation Factor Xa. J. Med. Chem. (2001) 44(4): 566–578.
- •A recent paper on DuPont's new potent orally-active FXa inhibitors.
- UEDA N, MIDORIKAWA A, INO Y etal.: Inhibitory effects of newly synthesized active center-directed trypsin-like serine protease inhibitors on the complement system. Inflamm. Res. (2000) 49 (1):42–46.
- MORTY R, TROEBERG L, PIKE R et al: A trypanosome oligopeptidase as a target for the trypanocidal agents pentamidine, diminazene and suramin. FEBS Lett. (1998) 433(3):251–256.
- Heterocycle derivatives that inhibit Factor Xa. Exp. Opin. Ther. Patents (1998) 8(101359–1365.